-
Tasly Pharmaceuticals Gets NMPA Approval for STRO-002 Clinical Study in Solid Tumors
•
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its third-generation antibody drug conjugate (ADC), STRO-002, in advanced malignant solid tumors. STRO-002: A Third-Generation ADC Targeting FRαSTRO-002, originated by US firm Sutro Biopharma Inc.,…
-
CanSino Biologics to Expand Southeast Asian Presence with Solution Group Berhad Stake
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) is poised to acquire an undisclosed amount of shares in Malaysia-headquartered Solution Group Berhad, a strategic move aimed at expanding its market footprint in Southeast Asia. Collaboration in the Vaccine SectorPreviously, CanSino Bio entered into a partnership with Solution’s subsidiary, Solution Biologics Sendirian…
-
Youcare Pharmaceutical’s YKYYO17 Receives Ethical Approval for COVID-19 Treatment Study
•
China-based Youcare Pharmaceutical Group (SHA: 688658) has received ethical approval from the China-Japan Friendship Hospital to conduct a Phase II/III study assessing the efficacy and safety of its YKYYO17 aerosol inhalation agent as a potential treatment for mild-to-moderate COVID-19. The drug candidate is a broad-spectrum coronavirus membrane fusion inhibitor polypeptide…
-
Novartis Defends Entresto Patents as Generic Approvals Trigger Legal Response
•
On August 24, 2023, generic versions of Novartis’ (NYSE: NVS) heart failure therapy Entresto (sacubitril, valsartan) received market approvals, with Chinese firms Nanjing F&S Pharmatech Co., Ltd and CSPC Pharmaceutical Group Ltd (HKG: 1093) receiving the honors. This development prompted a statement from Novartis on August 28, 2023, asserting that…
-
Jiangsu Hengrui Submits Market Approval Filing for SHR0302 in Ankylosing Spondylitis
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing has been made in China for its drug candidate SHR0302, intended to treat active ankylosing spondylitis in patients who have responded poorly to non-steroidal anti-inflammatory drugs (NSAIDs). Phase II/III Study Results Support FilingThe filing is…
-
CSH MEDI Secures Series A+ Funding to Advance Biomagnetic Equipment Technology
•
CSH MEDI, a Shanghai-based biomagnetic equipment manufacturer, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The sole investor in this round was XinDing Capital. The proceeds from this funding will be allocated towards research and development, as well as the iteration…
-
Junshi Biosciences’ Senaparib NDA Accepted by NMPA for Ovarian Cancer Maintenance Treatment
•
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has announced that the New Drug Application (NDA) for senaparib (JS109/IMP4297), a PARP inhibitor co-developed with compatriot firm Impact Therapeutics Inc., has been accepted for review by the National Medical Products Administration (NMPA). The intended indication is for use as a maintenance treatment…
-
Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced its financial report for the first half of 2023, along with key business updates. The company reported revenues of RMB 261 million (USD 29.8 million) for the period, marking an 18.4% year-on-year (YOY)…
